Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Price Crosses Above 200 Day Moving Average - What's Next?

Key Points

• Vanda Pharmaceuticals' stock price surpassed its 200-day moving average, reaching a high of $5.40, with current trading at $5.38.
• Wall Street analysts have mixed views, with ratings ranging from a "strong sell" by Wall Street Zen to a "buy" with a target price of $20.00 from HC Wainwright, resulting in an average rating of "Moderate Buy."
• The company reported poor quarterly earnings, missing EPS estimates and forecasting a negative return, with projected FY 2025 EPS of -1.12.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $4.56 and traded as high as $5.40. Vanda Pharmaceuticals shares last traded at $5.38, with a volume of 461,034 shares trading hands.

Wall Street Analysts Forecast Growth

VNDA has been the subject of several research analyst reports. Wall Street Zen downgraded shares of Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Saturday, August 2nd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, October 8th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a research report on Thursday, August 21st. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Vanda Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $16.50.

Vanda Pharmaceuticals Trading Up 2.9%

The business has a fifty day simple moving average of $4.75 and a 200 day simple moving average of $4.56. The stock has a market capitalization of $317.90 million, a P/E ratio of -4.76 and a beta of 0.74.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.12). Vanda Pharmaceuticals had a negative return on equity of 12.89% and a negative net margin of 32.90%.The company had revenue of $52.59 million for the quarter, compared to the consensus estimate of $54.77 million. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Institutional Trading of Vanda Pharmaceuticals

Several institutional investors have recently made changes to their positions in VNDA. CWM LLC grew its position in Vanda Pharmaceuticals by 424.6% in the 2nd quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company's stock worth $44,000 after purchasing an additional 7,575 shares in the last quarter. PVG Asset Management Corp bought a new position in shares of Vanda Pharmaceuticals in the first quarter valued at approximately $48,000. Linden Thomas Advisory Services LLC bought a new position in shares of Vanda Pharmaceuticals in the first quarter valued at approximately $49,000. Nations Financial Group Inc. IA ADV bought a new position in shares of Vanda Pharmaceuticals in the first quarter valued at approximately $67,000. Finally, Cerity Partners LLC bought a new position in shares of Vanda Pharmaceuticals in the second quarter valued at approximately $69,000. Institutional investors own 88.14% of the company's stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.